IRM three-lens brief
Evidence-based stock research on IRM. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Outperforming SPY by 9.5pp over 30 days. · P/E of 136 — priced for high growth; little margin of safety.
- Outperforming SPY by 9.5pp over 30 days.
- P/E of 136 — priced for high growth; little margin of safety.
- Negative free cash flow last quarterly (-$499.46M).
IRM closed at $125.47 (-0.59%) as of 2026-05-13. Market cap: $37.33B. P/E (trailing) 136.4. Positives: outperforming SPY by 9.5pp over 30 days.. Concerns: p/E of 136 — priced for high growth; little margin of safety.; negative free cash flow last quarterly (-$499.46M).. Last quarter: Revenue $1.94B, net income $143.66M, free cash flow -$499.46M.
Why three lenses on IRM, not one.
A single reasoning model has blind spots it doesn’t know about. We examine IRMacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/IRM" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath IRM brief"></iframe>